How long do you need to take Bosutinib?

Bosutinib/Bosutinib (Bosutinib) is a targeted therapy drug mainly used to treat chronic myeloid leukemia (CML). As a Bruton's tyrosine kinase (BCR-ABL) inhibitor, bosutinib prevents the proliferation of leukemia cells and promotes their apoptosis by inhibiting the tyrosine kinase activity of the BCR-ABL fusion gene product. The drug has been approved in many regions around the world and has become an important drug option for the treatment of CML.

For CML patients, the recommended dose of bosutinib is once daily, taken orally with food. Patients should swallow the medication whole and should not cut, crush or chew the tablet to ensure the potency and stability of the medication. The duration of bosutinib treatment depends on the patient's specific condition, efficacy, and tolerability. In general, bosutinib treatment should be continued until disease progression or adverse effects make continuation of treatment unavailable.

Generally speaking, when bosutinib is used to treat CML, it requires long-term and continuous administration. For those CML patients in the chronic phase, bosutinib is usually used as long-term maintenance therapy, with the goal of maintaining the patient's remission state and prolonging disease-free survival as much as possible by long-term inhibition of cancer cell proliferation. In some patients, continued treatment helps prevent leukemia from coming back and progressing. However, if the patient experiences worsening of the disease during treatment or is unable to tolerate the side effects of the medication, the treatment regimen may be adjusted.

During a patient's treatment, regular hematology monitoring is crucial to evaluate the effectiveness of treatment. By monitoring patients' leukemia-related indicators, such as white blood cell count and levels of BCR-ABL fusion genes, doctors can help doctors evaluate the effects and side effects of the drug, and then decide whether to continue treatment or adjust the dosage.

Keyword tag:

Bosutinib, Bosutinib, chronic myelogenous leukemia, CML treatment, maintenance therapy, BCR-ABL inhibitor, leukemia treatment, drug treatment duration

Reference materials:https://labeling.pfizer.com/ShowLabeling.aspx?id=17463